Zhejiang Hisun Pharmaceutical Co Ltd (600267.SS)

600267.SS on Shanghai Stock Exchange

23 Mar 2018
Change (% chg)

¥-0.51 (-3.44%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Zhejiang Hisun Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of specialty bulk pharmaceutical chemicals and preparation products. The Company's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infec... (more)
No analyst recommendations are available for .


Beta: 1.17
Market Cap(Mil.): ¥12,262.25
Shares Outstanding(Mil.): 965.53
Dividend: 0.05
Yield (%): 0.39


  600267.SS Industry Sector
P/E (TTM): -- 30.94 32.74
EPS (TTM): -0.10 -- --
ROI: 0.90 14.83 14.37
ROE: -1.49 16.33 16.07

BRIEF-Zhejiang Hisun Pharmaceutical to swing to profit in FY 2017

* Sees to swing to net profit at 10 million yuan to 15 million yuan in FY 2017 versus net loss at 94.4 million yuan year ago

31 Jan 2018

BRIEF-Zhejiang Hisun Pharmaceutical and unit obtain high-tech enterprise recognition and to enjoy tax preference

* Says it and unit were recognized as high-tech enterprise, and to enjoy a tax preference of 15 percent for three years

04 Jan 2018

BRIEF-Zhejiang Hisun Pharma Adjusts Private Placement Plan, To Raise Up To 940.9 Mln Yuan

* SAYS IT ADJUSTS A-SHARE PRIVATE PLACEMENT PLAN, TO RAISE UP TO 940.9 MILLION YUAN ($144.66 million) Source text in Chinese: http://bit.ly/2zLTZwE Further company coverage: ($1 = 6.5040 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

29 Dec 2017

BRIEF-Zhejiang Hisun Pharmaceutical's share trade to resume after Pfizer exited China JV

* SAYS SHARE TRADE TO RESUME ON NOV 29 AFTER PFIZER EXITED CHINA JOINT VENTURE WITH THE COMPANY Source text in Chinese: http://bit.ly/2iZ534b Further company coverage: (Reporting by Hong Kong newsroom)

28 Nov 2017

BRIEF-Zhejiang Hisun Pharmaceutical passes FDA approval

* Says it received approval for a kind of tablet from U.S Food and Drug Administration

21 Nov 2017

BRIEF-Zhejiang Hisun Pharmaceutical to issue up to 3.0 bln yuan commercial paper

* Says it plans to issue up to 3.0 billion yuan ($452.59 million) ultra-short commercial paper

20 Nov 2017

BRIEF-Zhejiang Hisun Pharmaceutical unit says product gets FDA approval

* Says co's Hangzhou-based unit's product simvastatin tablets, gets approval from U.S. Food and Drug Administration

20 Nov 2017

Pfizer exits China joint venture for generic drugs

Nov 10 Pfizer Inc said on Friday it has sold its 49 percent stake to exit a joint venture it had set up with China's Zhejiang Hisun Pharmaceuticals in 2012 to develop and market generic drugs.

11 Nov 2017

BRIEF-Zhejiang Hisun Pharmaceutical receives TGA-GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Therapeutic Goods Administration

11 Oct 2017

BRIEF-Zhejiang Hisun Pharmaceutical to invest 5.1 mln yuan to set up investment management JV

* Says it will invest 5.1 million yuan to set up Zhejiang-based investment management JV, which will be engaged in operation of pharmaceutical industry innovation projects, and hold 51 percent stake in JV after transaction

27 Sep 2017

Earnings vs. Estimates